<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p89" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_89{left:130px;bottom:1195px;letter-spacing:0.22px;}
#t2_89{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_89{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_89{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_89{left:293px;bottom:1066px;}
#t6_89{left:321px;bottom:1067px;letter-spacing:-0.01px;}
#t7_89{left:321px;bottom:1047px;letter-spacing:-0.01px;}
#t8_89{left:293px;bottom:1018px;}
#t9_89{left:321px;bottom:1018px;letter-spacing:-0.01px;}
#ta_89{left:321px;bottom:999px;letter-spacing:-0.01px;}
#tb_89{left:293px;bottom:950px;}
#tc_89{left:321px;bottom:950px;letter-spacing:-0.01px;}
#td_89{left:238px;bottom:902px;letter-spacing:-0.01px;}
#te_89{left:238px;bottom:867px;letter-spacing:-0.01px;}
#tf_89{left:238px;bottom:848px;letter-spacing:-0.01px;}
#tg_89{left:238px;bottom:828px;letter-spacing:-0.01px;}
#th_89{left:238px;bottom:809px;letter-spacing:-0.01px;}
#ti_89{left:238px;bottom:790px;letter-spacing:-0.01px;}
#tj_89{left:238px;bottom:735px;letter-spacing:-0.01px;}
#tk_89{left:238px;bottom:716px;letter-spacing:-0.01px;}
#tl_89{left:238px;bottom:681px;letter-spacing:-0.01px;}
#tm_89{left:238px;bottom:662px;letter-spacing:-0.01px;}
#tn_89{left:238px;bottom:642px;letter-spacing:-0.01px;}
#to_89{left:238px;bottom:623px;letter-spacing:-0.01px;}
#tp_89{left:238px;bottom:569px;letter-spacing:-0.01px;}
#tq_89{left:238px;bottom:549px;letter-spacing:-0.01px;}
#tr_89{left:238px;bottom:530px;letter-spacing:-0.01px;}
#ts_89{left:238px;bottom:511px;letter-spacing:-0.01px;}
#tt_89{left:238px;bottom:491px;letter-spacing:-0.01px;}
#tu_89{left:238px;bottom:472px;letter-spacing:-0.01px;}
#tv_89{left:238px;bottom:452px;letter-spacing:-0.01px;}
#tw_89{left:238px;bottom:433px;letter-spacing:-0.01px;}
#tx_89{left:238px;bottom:413px;letter-spacing:-0.01px;}
#ty_89{left:238px;bottom:394px;letter-spacing:-0.01px;}
#tz_89{left:238px;bottom:375px;letter-spacing:-0.01px;}
#t10_89{left:238px;bottom:281px;letter-spacing:-0.01px;}
#t11_89{left:238px;bottom:262px;letter-spacing:-0.01px;}
#t12_89{left:238px;bottom:243px;letter-spacing:-0.01px;}
#t13_89{left:238px;bottom:223px;letter-spacing:-0.01px;}
#t14_89{left:238px;bottom:204px;letter-spacing:-0.01px;}
#t15_89{left:238px;bottom:184px;letter-spacing:-0.01px;}
#t16_89{left:238px;bottom:165px;letter-spacing:-0.01px;}
#t17_89{left:238px;bottom:145px;letter-spacing:-0.01px;}
#t18_89{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_89{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_89{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_89{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_89{font-size:14px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts89" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg89Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg89" style="-webkit-user-select: none;"><object width="908" height="1286" data="89/89.svg" type="image/svg+xml" id="pdf89" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_89" class="t s0_89">7.7. Residual tumor, recurrence and recurrent metastasis </span><span id="t2_89" class="t s1_89">89 </span>
<span id="t3_89" class="t s2_89">For this purpose, the following qualitative criteria were used 12 weeks after </span>
<span id="t4_89" class="t s2_89">chemoradiotherapy: </span>
<span id="t5_89" class="t s3_89">• </span><span id="t6_89" class="t s2_89">Incomplete nodal response – intense focal FDG uptake with or without cervical </span>
<span id="t7_89" class="t s2_89">lymph node enlargement, </span>
<span id="t8_89" class="t s3_89">• </span><span id="t9_89" class="t s2_89">Questionable (doubtful) nodal response to therapy – low or no focal FDG uptake </span>
<span id="ta_89" class="t s2_89">in enlarged neck lymph nodes or low uptake in normal-sized neck lymph nodes, </span>
<span id="tb_89" class="t s3_89">• </span><span id="tc_89" class="t s2_89">Complete nodal response to therapy – all unremarkable FDG-PET-CT findings. </span>
<span id="td_89" class="t s2_89">In the planned neck dissection group, the operation was performed regularly. </span>
<span id="te_89" class="t s2_89">The median follow-up interval was 36 months. Fewer neck dissections were performed in the </span>
<span id="tf_89" class="t s2_89">FDG-PET-CT based surveillance group compared to the planned neck dissection group (54 </span>
<span id="tg_89" class="t s2_89">versus 221). The surgical complication rate was almost the same in both groups (42% versus </span>
<span id="th_89" class="t s2_89">38%). The 2-year overall survival rate was 84.9% (CI95% [80.7-89.1]) in the surveillance group </span>
<span id="ti_89" class="t s2_89">and 81.5% (CI95% [76.9-86.3]) in the planned neck dissection group. </span>
<span id="tj_89" class="t s2_89">The non-inferiority of FDG-PET-CT surveillance compared to planned neck dissection was </span>
<span id="tk_89" class="t s2_89">statistically significant (p=0.004). </span>
<span id="tl_89" class="t s2_89">The Mehanna study [114] also showed that the surveillance group had a small advantage in </span>
<span id="tm_89" class="t s2_89">general health status (EORTC QLQ-C30) 6 months after randomization compared to the neck </span>
<span id="tn_89" class="t s2_89">dissection group. However, this difference became significantly smaller after 12 months, so that </span>
<span id="to_89" class="t s2_89">there was finally no difference between the two groups (p=0.85). </span>
<span id="tp_89" class="t s2_89">If a tumor manifests again after a tumor-free interval following surgery and/or </span>
<span id="tq_89" class="t s2_89">radiochemotherapy, this is referred to as a recurrence, in contrast to a residual tumor, in which </span>
<span id="tr_89" class="t s2_89">a residual tumor remains despite therapy. The previous therapy is of crucial importance for </span>
<span id="ts_89" class="t s2_89">further therapy planning. Residual and recurrent tumors of the larynx after radiotherapy have </span>
<span id="tt_89" class="t s2_89">already taken place are a serious clinical problem. They usually show aggressive growth, </span>
<span id="tu_89" class="t s2_89">unpredictable lymphogenous metastasis and are associated with poor local control. Residual </span>
<span id="tv_89" class="t s2_89">tumors and recurrent tumors after previous surgical therapy, on the other hand, are less </span>
<span id="tw_89" class="t s2_89">problematic, since both a further surgical treatment, possibly combined with adjuvant </span>
<span id="tx_89" class="t s2_89">radiochemotherapy, and radiochemotherapy alone are possible. Salvage surgery is used when </span>
<span id="ty_89" class="t s2_89">a residual tumor exists after primary radiochemotherapy. This can affect both the primary </span>
<span id="tz_89" class="t s2_89">tumor region and the neck lymph node metastases. </span>
<span id="t10_89" class="t s2_89">The time until a recurrence occurs depends not only on the tumor biology, but also on various </span>
<span id="t11_89" class="t s2_89">parameters of the primary therapy, such as the radiation dose. The majority of recurrences </span>
<span id="t12_89" class="t s2_89">occur within the first two years after primary treatment; recurrences that occur in the first 10 </span>
<span id="t13_89" class="t s2_89">months after primary treatment are associated with a particularly poor prognosis [6]. Curative </span>
<span id="t14_89" class="t s2_89">treatment options for recurrences and residues after primary radio(chemo)therapy include </span>
<span id="t15_89" class="t s2_89">laryngectomy, open partial laryngeal resection and transoral (laser) surgery, with </span>
<span id="t16_89" class="t s2_89">laryngectomy being the most frequently used treatment worldwide in the recurrence situation </span>
<span id="t17_89" class="t s2_89">[295]. </span>
<span id="t18_89" class="t s0_89">© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
